Skip to content

Clinical Evaluation of Traditional Chinese Medicine Intervention for Unstable Angina Based on Bi-Directional Cohort Study

Clinical Evaluation of Traditional Chinese Medicine Intervention for Unstable Angina Based on Bi-Directional Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000023
Enrollment
Unknown
Registered
2024-02-25
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unstable angina pectoris

Interventions

Chinese medicine combined with Western medicine group:Chinese medicine treatment (including Chinese herbal decoction, oral Chinese patent medicine and Chinese medicine injection) combined with Western

Sponsors

The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for unstable angina pectoris of coronary heart disease; 2. Hospitalized more than two times in the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from 2013 to May 2023, UA was treated with Western medicine or traditional Chinese medicine (including Chinese herbal decoction, oral Chinese patent medicine, and Chinese medicine injection) combined with western medicine during hospitalization. 3. Record at least one hospitalization in the three months before enrollment.

Exclusion criteria

Exclusion criteria: 1. Patients with valvular heart disease, various types of cardiomyopathy, malignant arrhythmia, and NYHA functional classification III-IV heart failure; 2. Patients with untreated or uncontrolled hypertension (BP=180/100mmHg); 3. Patients diagnosed with severe brain tumors or traumatic brain diseases; 4. Patients with acute cerebrovascular disease that occurred in the past two weeks; 5. severe pulmonary dysfunction (PaO2 2.0mm in diameter with > 50% stenosis)

Design outcomes

Primary

MeasureTime frame
Readmission density for cardiovascular related diseases;

Secondary

MeasureTime frame
All-cause mortality;Major adverse cardiovascular events (MACE);Seattle Angina Questionnaire (SAQ) score values;

Countries

China

Contacts

Public ContactDe Zhao Kong

The affiliated hospital of Liaoning University of Traditional Chinese medicine

dezhaok2007@163.com15998854687

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026